Summary
Management framed Alvotech as entering a launch-driven growth inflection, with facility remediation and first-wave positioning supporting its near-term pipeline.
Guidance
- $650M$650M revenue and $180M EBITDA at the lower end of 2026 guidance; excludes U.S. launches of three products expected in December
- 2026 guidance high end includes a moderate contribution from December U.S. shipments
What analysts pressed on
- 01FDA remediation: management cited three facility issues, more than 200 corrective actions, and three months without environmental-monitoring hits.
- 02FDA reinspection: management said another visit is possible but unnecessary technically; it remains ready and expects the six-month review clock.
- 03High-dose Eylea: management expects rest-of-world submissions this year but declined to specify U.S. launch timing before completing clinical work.
- 04Commercial opportunity: management argued Symphony and low-dose Eylea economics remain intact despite delays, citing settlements mainly in Q4 2026 or Q1 2027.
- 05Capacity: management said Fujifilm provides flexibility for clustered customer orders while Alvotech continues fully using its Iceland facility.
- 062026 guidance: the lower end excludes December U.S. launches, while the high end assumes moderate shipments.
Notable disclosures
- 40%40% Symphony market share in some European markets; management described uptake as strong.
- $7.5B~$7.5B Antivio opportunity; management said it knows of only one close developer and no other submitted application.
- Six of the next eight to nine launches are expected to be first-to-market or in the first biosimilar wave.
- More than 200 corrective actions addressed facility observations; management reported no environmental-monitoring hits during three months of follow-up.
Risks raised
- FDA previously issued CRLs for three pipeline BLAs over facility observations, creating launch-timing and regulatory uncertainty.
- FDA may reinspect the facility despite management's view that open items were addressed; the review clock runs to early December.
- Prolia/Xgeva may face tougher competition and lower gross margins than Symphony and Eylea.
- Keytruda is expected to be highly competitive, limiting its commercial attractiveness despite shared development costs.
Tone: Confident 0.78
Management emphasized restored regulatory confidence, upcoming launches, and first-wave pipeline opportunities, while acknowledging competition and prior FDA setbacks.
Who spoke
Company
- Robert WestmanExecutive Chairman
- BalajiChief Financial Officer
Analysts
- Matt DellatorreAnalyst, Goldman Sachs
Full transcript
Analyst questions are marked with a bar. Timestamps are into the recording.
Prepared remarks
Matt DellatorreAnalyst, Goldman Sachs
Great. Well, good morning, everyone, and thank you for joining us. My name is Matt Dillatorre, and I'm a biopharma analyst here at Goldman Sachs, and we're very pleased to continue the next session this morning with Alvatec, where I'm joined by Robert Westman, founder and executive chairman, and Balaji Prasad, chief strategy officer. Robert and Balaji, thank you for being here.
Robert WestmanExecutive Chairman
Thank you for listening.
BalajiChief Financial Officer
Thanks for inviting. think.
Matt DellatorreAnalyst, Goldman Sachs
Maybe to start, Robert, before we get into specific programs, and I know you guys had announcements this morning, and you made a big announcement last week. Maybe just for those of us less familiar with Alvo, give us a brief overview of the company, and then frame for us where you all stand today, kind of like your key priorities, and how you're thinking about the outlook and strategy over the next couple of years.
Robert WestmanExecutive Chairman
Yeah, yeah, yeah. It's a very good question. And, yeah, so I founded the company in 2013, and the vision has been building a pure-play biosimilars, not focusing on anything else. We wanted to build end-to-end R&D in-house, from satellite development to developed BLAs. We wanted also to have all the manufacturing in-house.
Those two elements were always critical to us because it's a fairly complex product to develop, and those are also very complex to manufacture, to have it all in-house. So we have invested in R&D and manufacturing close to $2 billion since we started 2013, and the company went commercial for the first time in U. S. mid-2024. So the company is fairly young on the market, But we have been building all the infrastructure, and what we have is a portfolio of 30 products, which we believe is the broadest portfolio in the industry, if you will. We have launched five products outside the U. S. We have two products on the market in the U. S. , and by later this year or late this year, we expect to launch another three products into the U. S. And then, of course, a few of the submissions we will talk about, I'm sure.
Matt DellatorreAnalyst, Goldman Sachs
Super exciting. And our aim is always to be in the first wave or be first to market. And we have all the infrastructure now which we can engage. We have commercial partners which are covering more or less every market in the world. so we can roll out our products into 80, 90 markets and compete with the brands.
So holistically, it's all coming nicely together, and the company is at a massive inflection point, we believe, now after we resubmitted the three BLAs into the U. S. Great. Yeah, maybe kind of diving into those resubmissions last week and some of the news this morning. You guys made a pretty material announcement last week that you've resubmitted your BLAs for Biosimilars, Sympony and ILEA.
I think many people were expecting this closer to the end of the month. So maybe this came a little earlier than we all expected. Maybe walk us through how you got here and kind of how significant this is for you all.
Robert WestmanExecutive Chairman
Yeah, I mean, we are operating globally. So we basically, currently our facility is approved by all major regulatory health authorities in the world, including USFDA. It was unfortunate that we got a CRL in the first round of the three pipeline products. There was no comments on the BLAs themselves, but there were some comments on the facility. we have of course worked over 10 months in details to fix what we felt we needed to fix to make sure that we would not be in a position again to receive a CRL so a lot of work has gone into that we resubmitted last week by a similar to Symfony we are the first and the only one in Europe We have launched now with our partner in Europe.
We are seeing a very strong uptake in markets here. We are up to 40% in some of the markets. We are seeing strong market uptake in Germany and Scandinavia and elsewhere.
We have one competitor which we believe will launch in Europe one day, and the same one might launch into the U. S. but we think we are in the first wave, potentially still first to market with Biosimilator Symphony in the U. S. And then we are launching ILEA, Biosimilator ILEA, and then ProLEA X-Giva. So that will drive the growth of the business next year and going forward, but more importantly, the submissions and the filing acceptance by FDA and TIVIO is a really, really big milestone for us.
BalajiChief Financial Officer
And Matt, so I think on the question that you asked, said, right, that most investors are expecting this towards the end of the month and now, I think it was also because we had this FDA inspection last month, which we cleared very successfully, And so investors were wondering if because of that we will be pushed out beyond June 2. And we are very happy to assure our investors that the observations that we had, few observations were manageable.
And more importantly, the FTA also went through a lot of very comprehensively and that we are filing it on time in June, in the first week of June, signals that the inspections were really solid. And that's why the market also reacted the way it did and has more confidence in us now, and today's news on AVT-16 was like an icing on the cake. So really important to know that.
Matt DellatorreAnalyst, Goldman Sachs
Great, yeah. Could you maybe remind us a little bit about what you implemented, and then can you talk about any kind of safeguards that are in place now to prevent any kind of similar issues?
Robert WestmanExecutive Chairman
Yeah, maybe. So basically when you go through an inspection, you answer the 483s, and then FDA sends you a PAL letter stating what they felt were missing to basically approve your new filings. There were three main issues there. First was the rubber stopper in our services. So we have a German-made machine from Bosnia-Straupol, which I think every second sterile manufacturer has.
So this machine requires a pharmaceutical-grade silicone to lubricate when you start to operate the machine, especially with the rubber stopper, so they flow through the machine. FDA didn't like that. I think this might be a new theme, and we are most likely the first one to receive that one. But how that ended is that we managed in the end after, you know, stopping for a couple of weeks to operate the machine without any lubrication. So that was our answer to that.
We are, of course, new in the market, as I said, in the U. S. We had complaints in the U. S. over 500, 600 auto injectors. At that time, we had produced 5 million. which proportionally is very small. But the overall FDA wanted us to tighten up the process, how we follow up to receive some of the faulty pen back.
Because in the U. S. , as you might know, if you dial into your pharmacy, you claim that your pen is faulty, you get a new one. And the patients are not often giving the pens back which in the end we need to investigate But we believe we have both internally and with the process itself so far pen as Vekovie and it's from Ipsomet in Switzerland and we have not had any mechanical issue with the pen to be honest. And then And then when it comes to the third point, which is general environmental monitoring, we had hits in the facility all below action limits, which means that they are not critical enough to be above action limits.
But still, we wanted to have fewer of them. And collectively, we have implemented over 200 KBAs to fix that. And we submitted, resubmitted with three months data where we did not have any hits anywhere, even though we are looking at only below action limits. So I think we have addressed the fundamental, of course, what was pending, but more important, the fundamental of this facility. So I think we have gone over and above simply to make sure that we are not going to end up in a similar situation with the CRL.
Matt DellatorreAnalyst, Goldman Sachs
Great. And then your biosimilar Prolia and Xgeva, I think they were not included with this resubmission. What are your kind of expectations in terms of timelines for filing?
Robert WestmanExecutive Chairman
Sure. Sure. So Prolia and Jiva is the marketing, the authorization is with Dr. Redis, our partner. So in the U. S. , for most parts, we are partnered with Tava, and this one is with Redis, and so they will be filing, which will be in a minute.
Matt DellatorreAnalyst, Goldman Sachs
Great. Maybe lastly on Symphonia and Ilea, you know, the FDA just completed, I think, a routine CGMP surveillance inspection at Reykjavik. I guess, how do you view the likelihood of another re-inspection?
Robert WestmanExecutive Chairman
Yeah, it's an interesting question. So basically, we believe that the FDA went through all the open items from the PAL letter. we did not get any comments or outstandings on the BLA itself so technically they would not have to come but we know that FDA has their own agenda but what we have said it does really matter to us if they come or not we are ready to receive FDA and we would just welcome them if they come but they could also decide not to come. But it's a six-month clock. We expect that FTA generally is using the six months, so it's early December, which allows us to launch the three products into USB for year-end.
Matt DellatorreAnalyst, Goldman Sachs
Got it. Maybe shifting over to the Antivio update, this morning you guys had a big announcement there. Maybe you can just walk us through the update and then You recently submitted an MAA to the EMA for the biosimilar in Europe. I guess, how are you thinking about the opportunity in both Europe and as well as the U. S.?
BalajiChief Financial Officer
Sure. So this is something that we're really excited about. We are very happy that the submission and the acceptance of it came through. and it's one of our most important near-term to medium-term opportunities that we have discussed about in the past. For context, the global market size of this is pretty large. It's around $7 billion and has a sizable market in the U. S. , right? And we expect to be in not just one of the first markets but also going to be a limited competition for quite a while. So we are really happy to have this around and, of course, set the clock for a 12-month approval timeline from the date of submission, right?
So it could be one of our critical launches that we'll be looking forward in the near term itself.
Robert WestmanExecutive Chairman
Yeah, I just want to underline what Palazzi said. I mean, we have their $7.5 billion opportunity we believe there is only one developer which is close to us we are not aware of anyone which have submitted we have also the SAPQ version of the product which is important so all in all we believe that for most markets this will be announced next year for us.
BalajiChief Financial Officer
And so I want to underline what Balasi said. I mean, we are super excited about this opportunity. And this is by far the biggest opportunity in our short history of being commercial, which is coming up.
Matt DellatorreAnalyst, Goldman Sachs
Great.
Robert WestmanExecutive Chairman
You know, and you touched on this a bit, but, you know, I guess in that context, how are you thinking about the opportunity for, you know, Symponi, ILEA low dose and Prolia X-Jiva yeah I mean overall I think Symfony us being alone of course outside the US still today it's being shown to be a good opportunity and being either first or one of two in the US will also be very exciting but again Symfony is around 3 billion product.
BalajiChief Financial Officer
So just from size perspective, Antibio most likely will be even more exciting, if you will. We think with the low-dose idea, there is still a strong market for the product, and we think we will be in a good position. I mean, we know that Amgen has been super successful in the US, and we have launched the product now into the UK with a pretty strong market share just in a couple of months, over 5%, and we have rolled out the product into the European Union, so excited about that.
Prolix Giva, we have always seen as more competitive and that product was one of our first ones to develop, So we ended finishing it, but from gross profit, gross margin, I think for everyone it will be more comparative to the other two.
And in terms of market opportunity on both of these, so I think investors also tied up the fact that we didn't get to the market at the end of Q425 or as we thought. But the commercial opportunity of both of these, especially Symfony and Ilia, they're very much intact because most of the settlements are towards Q4, 2026 or Q1, 2027 and will be coming in with the next wave of launches. So the Ilia commercial opportunity, even if it had gotten approval last year, would still be very much the same and intact.
And with Symfony, again, there's only one other filer who got approved a couple of weeks ago and they have stated that they will be launching in Q4, 2026, which with the resubmission that we announced last week, we expect to basically be in the first wave, if not the first to market with Symfony still. So the commercial opportunity is something which is very much intact and which clearly the market misread or misunderstood the situation there. So that's, again, I think important to highlight, Matt.
Great. And then maybe kind of in the context of low-dose ILEA, and I think you guys are also pursuing high-dose ILEA. How are you thinking about the timelines and that relative opportunity?
Robert WestmanExecutive Chairman
Yeah so I think Alba Tech has been one of the pioneers to adjust to the changes of the brands So we were the first to adopt from low-dose to high-dose on Baja Semulatuhi Humira. And we went into Antibio with a sub-Q when we saw the brand going there.
We also, when we saw that Regeneron was going to launched a high dose, 8 mg. We basically internally, before the product came to market, made five, six prototypes in-house. And when the product then launched, one of our formulation was a perfect formulation from both maths and IP standpoint. so we always expected to be in the lead we have seen 40% conversion in Europe 40% conversion in the US and that conversion we believe will continue and we saw that Amgen announced that they are starting their clinicals for US in June and we have already been working on our clinical, so we should be ahead of them in the U. S. And we are pretty imminently filing already into the rest of the world markets with the product.
And what is also interesting is that the safety device or the Ocuclid which they have been developing, we have spent two years on a similar device. So I think we will be in an absolutely pulled position when it comes to high dose alia. I'm super excited about that.
Matt DellatorreAnalyst, Goldman Sachs
In terms of timing?
Robert WestmanExecutive Chairman
We will be submitting in the rest of the world this year, and I would not rule out that that could be a launch on approval. We are then finishing the clinicals for the U. S. market, so we will be submitting a bit later there.
Matt DellatorreAnalyst, Goldman Sachs
And then in terms of launch timing for U. S. , do you have any clarity on that?
Robert WestmanExecutive Chairman
I would not comment on that until our clinical is done, if you will. What we have said, though, is that it's one of our medium-term opportunities, and so definitely think about it in that time frame that we are really excited about and as a clear differentiator for us.
Matt DellatorreAnalyst, Goldman Sachs
And then maybe moving to another kind of mega blockbuster, Keytruda. Obviously, you know, very competitive market. But you guys recently, I think, you guys have a partnership with Dr. Reddy there.
Robert WestmanExecutive Chairman
Yeah. I guess maybe, you know, kind of walk us through the strategy for that molecule. Yeah, I mean, it was kind of, as we all know, it's the biggest molecule in the world. in our mind we wanted to have it in our pipeline to be able to offer it to our clients but knowing also how many companies were developing the product it in many ways was not commercially as lucrative as it would be with the less competition so we were kind of early adopter of stop doing the patient study or phase three study already.
We expected that we could skip the patient study for K-truda, which brought the cost substantially down. And then this is a code development with Dr. Redis, where they will be, in the end, producing the drug substance. So we are sharing the cost. We believe we will be more cost-comparative than most others. So that's kind of the approach we did to be in the product. But overall, I think it will be a pretty competitive molecule going forward.
Matt DellatorreAnalyst, Goldman Sachs
Great. Maybe switching over to business development, you all recently announced a partnership with Fujifilm Biotech. Expand your global manufacturing network. and I guess establishes a second source of commercial supply in both the U. S. and the U. K. Maybe can you elaborate on what drove the rationale for that deal?
Robert WestmanExecutive Chairman
Yeah, so it's a very good question. So we have one facility in Iceland. It's state-of-the-art, both drug substance, drug product, with a capacity we have set beyond 2030.
We have, though, five products on the market. We have 30 products in the pipeline, which we believe, again, is the strongest pipeline in the industry. When we saw the patient study would be not needed going forward over two years ago, we increased the capacity in cell line development, process development, and where we felt we had bottlenecks. bottlenecks. So we have been on the gate and starting new R&D program almost every second month for over two years. So when it comes to the capacity, we are seeing three launches in the U. S. end of this year. We are seeing that we are growing market share substantially outside the U. S. , especially for Biosimilar II Symphony.
We are seeing our good colleagues here, Teva, growing the shares in both Biosimilar II Humira and Stellara, which is nice to see. And then on top of that, we will be expecting to launch and TIVIO into multiple markets. And this will all come into a very similar timeframe. It will all happen, of course, throughout next year. So having Fujifilm as a partner, which mainly is working with Big Pharma, was something very valuable to us and will allow us to be more flexible in case we gain more market share if the order from our clients come in in the same quarter to be able to still deliver on that. So it was very strategic and long-term.
But, of course, we will be using our own facility at the same time fully. So we should think about it. It will be used for both commercial and pipeline products.
Matt DellatorreAnalyst, Goldman Sachs
Fuji, yeah. Absolutely. Okay. Great. Maybe kind of stepping back and looking at the biosimilar market a little more broadly, obviously the opportunity over the next decade is very significant, and kind of things have been changed. Regulatory-wise, you touched on some of the FDA changes, and then we've also seen changes on the payer side of private labels and things. I guess how do you guys kind of internally strategize and kind of think about the category overall in that context?
Robert WestmanExecutive Chairman
Yeah, I think if you start at the beginning, because it's a fairly young industry, if you will, as you know. So we saw quite a few players coming in at the beginning. And it was the same. I mean, I was the pioneer in the generic industry since 1999. I built ActaVis, AlvoGen, quite a number of generic companies. And we are starting a new era with biosimilars, as we did 26 years ago in generic, if you will. And it's only five, six years since really adoption in U. S. and market share gain started to happen for biosimilars.
We know those products are very effective but very costly. We're seeing the trend now that 40% of the $1.8 trillion farmer market is biologics. we are seeing in phase 2, phase 3 from the top 10 big pharma companies is biologic So basically we think we will see the trend from 40 to 50 and even 60 going forward At the same time, the earlier doctors, some of them are leaving the scene, if you will. We have seen Boehringer Ingelheim. We have seen Pfizer.
And we have seen others which are scaling down. One could say it's cheaper now to develop biosimilars, and the answer is yes.
It does cost still 60 to 90 million per product, and you need to build a facility which costs you half a billion at least. So it's a billion-dollar venture before you get really into it and usually take 10 years. So I'm not seeing necessarily, even though the regulations are changing a bit, that we will see a flood of new players coming in.
So all in all, I mean, this is a company like ours is really needed just to sustain healthcare systems around the world. We have the pipeline to basically grow and support markets in U. S. and Europe and where it is globally. So overall, I mean, we are extremely excited about our journey. which in many ways commercially is just starting.
BalajiChief Financial Officer
Yeah, and I think it's also important to note that though there's a CES waiver, the FDA may say, okay, CES waiver, but they're going to increase the scrutiny on all of the data that we submit for companies. And that really plays well for companies like us with a very strong R&D track record, a very strong process and analytical data capability to be able to showcase that. And this is not something that can be acquired by any new entrant overnight. So that really forms a moat to the industry and forms an entry barrier. That's something that we think that, especially some of the top incumbents like us, it helps for us to grow and capitalize into this explosive growth period in biosimilars that is coming up over the next 10 years now.
Matt DellatorreAnalyst, Goldman Sachs
And maybe how do you think in terms of how we'll actually see it play out with, you know, not requiring the phase threes? I mean, clearly some companies are still running Phase 3s, and if you read the FDA guidance, it's like make an argument for why you don't need it. So do you all imagine it will be essentially no one will be running Phase 3s in a few years, or it will be dependent on how?
Robert WestmanExecutive Chairman
I think it will be very exceptional if Phase 3 will be run going forward. and you need to have the analytical data to support that your product is interchangeable. And we have seen if you pass the PK, the phase three was not really adding anything into the development. That's why we expected this to come and this to happen, and that's why we adopted to it earlier than anyone else. and then I mean you asked about the market dynamics private labels like in US I mean that's a US thing it mainly applies to retail products with our pharmacy benefit we had Humira of course being the biggest one there are not too many pharmacy retail benefit products coming out so we are not really seeing the private label necessarily playing a big role going forward it did in Humira with different success between the three PPMs but overall we think it will still be especially when you have product more medical benefit it will still be you know some of the smaller ones both smaller PPMs and promotions and providing a quality product to the market, which will count.
Opportunity kind of outside of that channel.
Matt DellatorreAnalyst, Goldman Sachs
Yeah. Okay. Maybe turning to your guidance for the year, you gave 2026 guidance on the top line and then also EBITDA. But maybe walk us through kind of what expectations are built into those. And given kind of the recent developments, how should we think about changes to those?
Robert WestmanExecutive Chairman
Yeah, I mean, we gave a range. And in the lower end of the range, which is 650 and 180 EBITDA, we did not have any of the three products which we are launching now into December into the U. S. And because it's only one month, we took a moderate value being shipped to US on the high end. So that's kind of explaining the range.
But with the confidence we have in, of course, the US market, we strongly believe that we will be launching. So that was kind of the rationale when we gave out the guidance because the clarity was not fully there when we gave the guidance out a few months ago.
BalajiChief Financial Officer
Yeah, that said, despite the FDA and some of the slowdowns that we take on, we should still see, Matt, that even at the lower end of the range, we'll be at 26, and once the wave of launch is materialized, we will be in a significant period of growth over the foreseeable next few years. And we're really looking forward to that.
Matt DellatorreAnalyst, Goldman Sachs
Great, great. You know, you highlighted several times, you know, the biggest probably pipeline in the industry, but I think 30 molecules in the pipeline. Maybe kind of, you know, in the last few minutes, you know, walk us through what is, like, your strategy for selecting new molecules at this point? I mean, do you guys, you know, think of the revenue ranges?
Robert WestmanExecutive Chairman
No, it's a good question. I mean, we have always said we want to open up access for patients, and we are doing that in Alvotech. I've been doing that in my career for 26 years. So if you're going to open up on access, we need to come with a molecule which is still not widely open for biosimilars, and that's why you heard us talking about first with high-dose biosimilar to Humira, first with Antivio, first with SubQ, with Antivio, first with Symfony, first with Hidos, ILEA.
Because if you're not first or in the absolute first wave, you are kind of not opening up the access if there are already five, six, seven players. And so our portfolio strategy is evolved and developed around that. and as you can imagine you start a journey with a product and then we usually take five to seven years to develop a product and we closely monitor what the brand is doing and then very often we adjust to what the brand is doing to be able to open the access to the main strength or form of dosing they're adjusting to, if you will.
BalajiChief Financial Officer
I think also on Robert's point, he said earlier, it revealed some of the secrets out there. We have an exceptional R&D team, and that's why we have been able to get so many of these unique assets, be the first to market. So six of the next eight to nine launches that we are looking at over the next few years, near to medium term, they're all going to be, we are going to be either the first to market or in the first wave of bisimilars. And that is why earlier called out an explosive period of growth for us over the next few years.
And so we have, like, apart from these, we have Ilaris, we have Simzia, we have TALS. These are all assets which will have a strong revenue and debita contribution for us as we get to those periods.
Matt DellatorreAnalyst, Goldman Sachs
Great, great. Well, with that, Robert and Balaji, thank you both for joining us.
Robert WestmanExecutive Chairman
Yeah, thanks for the invitation.
BalajiChief Financial Officer
Pleasure.
Matt DellatorreAnalyst, Goldman Sachs
We look forward to watching the updates over the coming month. Thank you so much.
BalajiChief Financial Officer
Thank you so much, Matt, and Goldman for hosting us. Yeah. And great questions. Thank you. Yeah, thank you.
Other Alvotech earnings calls
- Q3 2026 earnings call
Management framed Q3 as a gradual supply recovery, with October FDA approvals improving capacity and productivity ahead of a potentially pivotal fourth quarter.
Nov 12, 2026Mildly positive0.35 - conference, September 15, 2026
Management framed Alvotech as entering a launch inflection point, with quality remediation behind it and selective direct U.S. commercialization alongside continued capacity flexibility.
Sep 15, 2026Positive0.68 - Q2 2026 earnings call
Management framed the half as a supply-constrained transition, with manufacturing restored to plan and execution now focused on rebuilding inventory and preparing launches.
Aug 20, 2026Positive0.55 - Q4 2025 earnings call
Management framed 2026 as an execution year, prioritizing FDA remediation, reliable supply, partner-led launches, and selective manufacturing diversification.
Mar 19, 2026Mildly positive0.35 - Q3 2025 earnings call
Management framed the call around a delayed Symphony approval and a deliberate production slowdown, while emphasizing that launch momentum and 2026 growth remain intact.
Nov 13, 2025Mildly positive0.20
About this transcript
The summary, guidance, analyst focus, and tone are automated and should be checked against the call before being relied on. Names and figures can be misheard. Listen to the replay.